Mirion Technologies, Inc. (MIR) Earnings Call Transcript & Summary
February 11, 2026
Earnings Call Speaker Segments
Eric Linn
executiveAll right, thanks, Melissa. Good morning, everyone, and I'm glad to welcome you to the call covering Mirion's results for the fourth quarter and the full year of 2025. With me today are Tom Logan, who founded Mirion and serves as Chairman and CEO, along with Brian Schopfer, our CFO and President of the Medical Group. Before we get into today's prepared remarks, I want to remind everyone that what we say on this call will contain forward-looking statements, and results that actually occur could end up differing materially from what those forward-looking statements project. You can read about the factors that might lead actual results to differ in our annual reports on Form 10-K, our quarterly reports on Form 10-Q, and Mirion's other SEC filings, specifically under the caption Risk Factors. When we refer to quarters in today's discussion, we mean the fourth quarter that ended December 31, 2025, unless we say otherwise. Comments on this call will also include certain financial measures that were not prepared in accordance with generally accepted accounting principles. You can find a reconciliation of those non-GAAP financial measures to the most directly comparable GAAP financial measures in the appendix of the presentation that accompanies today's call. All of our earnings materials are available in the Investor Relations section of our website at www.mirion.com. With that said, I'll hand things over to Tom, who is starting on Panel 3.
Tom Logan
executiveEric, thanks, and I appreciate everyone being on the call today. 2025 proved to be a robust year for Mirion, and it could not have happened absent the hard work, the energy plus the dedication shown by the whole Mirion team, so I thank all of you for what you put in and what you delivered. We recorded unprecedented orders during 2025, amounting to over $1 billion. The primary force behind this was the strength in the nuclear power market that we've kept emphasizing all year long. That figure includes $150 million coming from our sizable opportunity pipeline. Supportive macro conditions across both nuclear power and nuclear medicine fueled significant expansion in 2025. Organic revenue for nuclear power climbed by over 11% during the year, whereas organic revenue for Nuclear Medicine rose by over 13%. Entering 2026, double-digit organic growth is anticipated from both of these end markets. As you might remember, during 2025 we laid out a strategic priority aimed at boosting our nuclear power exposure. Toward that goal, we bought Certrec in July. Then in December, we completed the purchase of Paragon Energy Solutions. Each of these deals strengthens our North American nuclear power exposure and brings nuclear power revenue to approximately 40% of the overall figure. Crucially, that revenue is generated from fuel cycle, new plant construction, plant operations and decommissioning. Consequently, we span the full breadth of the century-long cradle-to-grave lifespan associated with a modern large-scale reactor. Crucially, roughly 80% of our revenue originates from the installed base, which faces both pressure and economic incentives to extend life, keep operating and modernize, which drives a corresponding rise in demand for the solutions Mirion offers; we see this dynamic as robust and not tied to any specific view regarding new build or SMR dynamics, because of the severe shortage in generating capacity across most developed markets. New builds and SMR ought to be viewed as appealing incremental opportunities layered atop the flow from the operating fleet, and our bullishness on this sector remains very high. We expect these key themes to keep developing further in 2026. Our sizable opportunity pipeline keeps expanding and should underpin favorable order dynamics throughout the year. We hold a right to win on over $400 million of large opportunity projects anticipated to be awarded during 2026, which includes $200 million of projects carried over from the 2025 pipeline. Finally, on this panel, I want to point out our 2026 full year guidance, which captures the strong fundamentals supporting our forecast, enabling rising revenues, expanding margins and improved adjusted free cash flow. I'll walk through a few of these points starting on Panel 4. As I said, we booked a record nearly $1.1 billion of orders in 2025. That marks a 26% rise compared with 2024. 2025 order growth plus the addition of Paragon's backlog produced a 36% increase in our backlog compared with last year. The nuclear power end market showed the strongest growth, backed by $150 million from our large opportunity pipeline. After that came $34 million in orders from defense and diversified end markets, mostly from the U.S. and with NATO. A drop in orders from the Labs and Research end market partly counterbalanced these 2 factors. During our previous call, I noted that DOGE along with the extended 43-day government shutdown dealt a blow to DOE orders in Q4. Our Medical segment likewise encountered certain headwinds in 2025, mainly because of difficult comps against the prior year combined with temporary macro headwinds. To explain further, nuclear medicine orders rose 31% in 2024, which created a hard comp for 2025. Even so, nuclear medicine orders fell just 6% in 2025. Dosimetry orders climbed 19% last year thanks to a sizable hardware order booked in 2024, which created a tough comp for 2025. Full year RTQA orders came in lower than 2024 because of a weak Japanese market and unfavorable capital spending trends in the U.S. health care market. On Panel 5, we lay out how we performed against 2025 guidance. Top line results were weaker than guidance because of softness in RTQA and labs and research. Even with the revenue shortfall, adjusted EBITDA hit target and showed margins expanding. Beyond that, free cash flow exceeded 2024's figure by more than two times and surpassed guidance on both an absolute basis and a conversion ratio basis. Adjusted EPS came to $0.46, a bit under the guidance range of $0.48 to $0.52, chiefly because of tax dynamics. Panel 6 covers the key drivers for the Labs and Research and RTQA end markets; our view is that the 2025 headwinds amount to a deferral of demand rather than a secular shift in the market. To be more specific, within Labs and Research, DOGE and the government shutdown are onetime effects that should equilibrate. In RTQA, the underlying market growth drivers remain in place, in particular an aging population demographic across developed economies and a growing push for higher standards of care in developing economies, both of which should drive overall demand growth. Our RTQA and nuclear medicine solutions stand to gain from this dynamic and make up roughly 75% of the segment's revenue. Panel 7 shows our robust historical track record. We've posted double-digit 5-year revenue and adjusted EBITDA CAGRs of 11% and 12%, respectively. What's more, adjusted free cash flow improved dramatically in 2025, doubling last year's performance and reaching our 2026 conversion target a year ahead of schedule; we anticipate further progress on all of these KPIs in 2026. Results for 2026 will get a boost from the recent acquisition of Paragon and Certrec, which we discuss on Panel 8. Through these 2 deals, we are widening our exposure to our most dynamic vertical and feel confident about the integration campaign. Both acquisitions instantly expand Mirion's footprint in the North American nuclear power market, greatly deepen customer intimacy and offer a major chance for us to bring their capabilities worldwide by drawing on our strong international presence. As with Mirion, the bulk of Paragon and Certrec's revenue stems from the operating fleet. Yet both acquisitions bolster our standing in the fast-changing SMR space. Paragon and Certrec together form the leading edge, with SMR developers backing licensing efforts, regulatory direction, and reactor instrumentation design. Right away, this has boosted the top-of-funnel opportunity set across Mirion as a whole and adds pull-through momentum for legacy Mirion offerings. Contractual commitments now exist with over 20 SMR developers, and our footprint keeps growing. We're putting in serious effort to run the tables so we can land and grow our standing with every key player. On this panel, as you can see, we've quantified appealing synergy opportunities and are advancing quickly. Come 2026, we'll move past foundational items such as finance, HR, and IT integration and pivot toward material synergy drivers, including commercial integration, better pricing heuristics, and supply chain optimization. Regarding that last one, we saw close to 100 basis points of adjusted EBITDA margin gain in 2025 by itself, thanks to procurement process improvement within legacy Mirion. We think a great deal of what we're doing here will carry over effectively to the Paragon and Certrec business models. Further ahead, commercial leverage and AI-informed product evolution make up the tail of the integration opportunity set, and our enthusiasm about the potential keeps building. Paragon additionally feeds our large opportunity project pipeline.
Tom Logan
executivePanel 9 makes clear that right now, we’re looking at over $400 million in sizable opportunities that could close in 2026. As the chart shows, that includes $200 million plus in fresh large projects, layered on top of $200 million carried over from 2025. What stands out is that close to half of those new opportunities are tied to Paragon. These projects are by definition $10 million or more, and beyond them, the wider nuclear power sector keeps creating growth potential for Mirion. Panel 10 highlights headlines from roughly the last month alone — whether that’s an $80 billion deal for new nuclear plants in the U.S. or fresh hyperscaler partnerships, market momentum keeps strengthening. It’s very evident that access to power is turning into an ever more essential issue for the world economy. Panel 11 shows that by 2035, almost 1/3 of all data centers are projected to surpass 1 gigawatt, versus just 10% today. To put that in perspective, every 1 gigawatt data center campus consumes roughly 1/5 of New York City’s total electrical load. Power generation and grid capacity are increasingly the constraints on data center expansion, and nuclear power will probably stay a key part of the long-term answer. Before I hand things to Brian to go through the financials, let me lay out our 2026 guidance on Panel 12. The key points are rising revenues, wider margins, and higher adjusted free cash flow. For 2026, total revenue should increase 22% to 24%. That figure includes FX tailwinds and acquisition-driven growth from Certrec and Paragon. Without those tailwinds, you get to our 2026 organic revenue growth outlook of 5% to 7%. Adjusted EBITDA guidance sits at $285 million to $300 million. That translates into adjusted EBITDA margins of 25% to 26%. And that margin range implies about 90 basis points of expected margin expansion this year, even with the dilutive margin effect from the Paragon deal. We expect to help Paragon turn margin accretive within our planning horizon, again, as we realize clearly identified synergies. Adjusted free cash flow for 2026 should be $155 million to $175 million. The anticipated increase mainly reflects the full-year benefit of higher earnings and improvements to the capital structure, which should more than offset a modest rise in expected CapEx to support AI and other key strategic initiatives. Lastly, 2026 adjusted earnings per share should be $0.50 to $0.57. That assumes about 275 million fully diluted shares, capturing a full year’s impact from the Paragon-related capital raise in September of 2025; also new this year, we’re now including stock-based comp in our adjusted EPS. If you excluded it as we did last year, our 2026 midpoint guidance would have been $0.61, or $0.07 higher. Brian will provide more detail on this and the broader financials. Brian?
Brian Schopfer
executiveThanks, Tom, and I appreciate everyone being on the call today. Starting with Slide 13, I'll walk through the financial results in detail. Enterprise revenue for the fourth quarter rose 9%, reaching $277.4 million, against $254.3 million in last year's fourth quarter. More than half of that year-over-year gain was driven by M&A. The figures include both Paragon's December results and a full quarter from Certrec. Currency movements gave total Q4 revenue a boost, adding 3.4% to the 9% increase over Q4 '24. Keep in mind that roughly 36% of our 2025 revenue is denominated in euros. Organic growth in the fourth quarter came in at 0.5%, held back by difficult comparisons in both segments, which we flagged on last year's fourth quarter call. In 2024, the Nuclear and Safety segment posted organic growth of 13.9%, which set up a tough comp. Within Medical, Nuclear Medicine rose 21% in Q4 '24, and dosimetry climbed 14% in Q4 '24. Adjusted EBITDA reached $77.6 million, an 11.5% increase over Q4 '24. Adjusted EBITDA margins widened 60 basis points even with the margin-dilutive effect of including Paragon for December 2025, our biggest month. Without Paragon, adjusted EBITDA margins would have come in at 28.6%, which is 120 basis points above last year. Q4 adjusted EPS was $0.15, which is $0.02 below Q4 '24; that reflects roughly 30 million shares added to our diluted share count from the convertible notes, plus about $20 million from the weighted impact of the equity raise that supported the Paragon acquisition completed at the end of Q3. There's a slide in the appendix showing how the converts behave at various stock prices. Adjusted free cash flow for Q4 was $78 million, which contributed to $131 million of adjusted free cash flow generation for the full year and 57% conversion. Full year results came in ahead of the initial 2025 guide. Q4 orders were up 62%, which reflects $140 million of large opportunity orders awarded during the quarter from the nuclear power end market. Even setting those orders aside, our Q4 order book was solid, up 11%. Slide 14 highlights the key nuclear power metrics for the year. Adjusted nuclear power orders rose 52% in 2025. That figure leaves out any acquisition-related orders and last year's turkey debooking. Growth in nuclear power orders was driven by all 3 verticals: new utility scale reactors, the installed base and SMRs; for example, we booked $39 million of SMR-related orders in 2025, versus $17 million in '23 and '24 combined. That momentum has carried into 2026, where we've already seen roughly $10 million of SMR orders in January alone. Organic revenue in the nuclear power end market grew 11% for the year, compared with 4.4% for the Collective Nuclear and Safety segment. We expect the nuclear power end market's organic revenue growth to again be double-digit in 2026. Slide 15 covers the Q4 order book details. As I mentioned, we booked $140 million of large orders in the quarter, among them the $55 million Asia installed base order we disclosed on our October earnings call. Beyond nuclear, orders in our defense and diversified end markets doubled during Q4, mostly within the U.S. and with NATO. The medical segment's orders were down for the quarter. Keep in mind that we faced difficult comparisons in both nuclear medicine and dosimetry end markets. Our large opportunity pipeline is bridged on Slide 16. Tom already addressed a good deal of this during his prepared remarks. What you can see here is how we got to the $200 million in previously communicated large opportunities, which represent part of the more than $400 million 2026 pipeline. Timing remains the unpredictable element here, and we feel our right to win is strong across all these projects. Moving to the P&L on Slide 17. Since we already went through Q4 in detail, we'll concentrate on full year results. Revenue for the full year came to $925.4 million, which is up 7.5% against 2024. Organic accounts for more than half of that growth. The remainder is split equally between M&A and FX. Nuclear power and nuclear medicine contributed meaningfully to organic revenue growth this year. Adjusted EBITDA for the full year was $227.9 million, rising 12% from 2024. For the full year, margins expanded 90 basis points, driven by procurement initiatives and operating leverage, partly offset by tariff and the impact from the Paragon acquisition, which closed in December 2025. Full year adjusted EPS came in at $0.46, a 12% increase, even with an approximately 50 million share increase in 2025 stemming from the convertible notes and the equity raise tied to the Paragon purchase. Slide 18 gives a 30,000-foot view of the factors that moved 2025 revenue relative to our initial guidance from December 2024. On the whole, FX and acquisitions were both tailwinds to revenue. Remember, we initially assumed a $1.05 euro to USD rate, while we finished the year at approximately $1.17. Also, the Certrec and Paragon acquisitions in the back half of 2025 contributed favorably to total revenue growth. On the other hand, top line performance took a negative hit from organic headwinds of approximately 250 basis points. The U.S. government shutdown and DOGE initiatives mostly affected our labs and research end market within the Nuclear Safety segment. And as we've been saying, our RTQA market was sluggish, largely because of hardware headwinds in North America, China and Japan, partially offset by how we performed in software and services. For instance, our RTQA services business posted a 2-year revenue CAGR of 12% from 2023 to 2025. Let's now move to the segments, starting on Slide 19. Q4 revenue for the Nuclear and Safety segment was $194.9 million, up 15.5%. Organic revenue rose 3.1% as the segment lapped a difficult 13.9% comp from last year. Q4 2025 organic revenue growth benefited from over 12% growth in the nuclear power end market, partially offset by ongoing softness in Labs and Research and, to a lesser degree, from the Defense and Diversified end market against a large 2024 comp. The Labs business was clearly affected by the 43-day government shutdown; we still believe this is a delay rather than a decline. We anticipate that returning to a more typical condition will require a certain amount of time, which you can observe in the organic revenue growth guidance located at the back of the deck. For the entire year, revenue in the Nuclear and Safety segment came to $614.6 million, which is a 9.5% increase over 2024. The full-year organic growth number mirrors an 11% rise in nuclear power, partly counterbalanced by an 8.5% drop in the global labs and research end market. To put a finer point on it, our U.S. labs business, which is tied predominantly to the DOE, fell roughly 15% across the year. On top of that, the defense portion of our Defense and diversified end market shrank, even as the industrials portion expanded. Even more significantly, if we had held Paragon during 2025, its growth on a year-over-year basis would have been 20%. Looking ahead to 2026, that figure is anticipated to reach approximately 25% plus. Adjusted EBITDA for the Nuclear Safety segment in Q4 stood at $60 million, or 13.6% above the prior year. Margins in Q4 contracted by 50 basis points. As we have mentioned, we completed the Paragon acquisition on December 1, and that weighed on Q4 margins. If you set aside Paragon's December results, Q4 margins would have grown by 50 basis points instead, driven by operating leverage, reduced incentive compensation and procurement initiatives. For the full year, adjusted EBITDA in the Nuclear and Safety segment reached $177.7 million, or 11.2% above the prior year.
Brian Schopfer
executiveMargins for the entire year likewise rose, climbing 40 basis points. Once more, if you set aside Paragon's December results, the margin improvement for the full year would have come in at 70 basis points, which is a 30 basis point swing. Moving on now to the Medical segment, which is on Slide 20. Revenue for the Medical segment in Q4 fell 3.5%, landing at $82.5 million. Back on the October earnings call, our expectation was roughly flat revenue for Q4. For Q4 RTQA organic revenue growth — revenue was down 4%. What accounted for the gap was that the RTQA end market took a hit from hardware headwinds in Asia and Europe. On top of that, as I noted before, nuclear medicine and dosimetry were running into difficult comps. For the whole year, Medical segment revenue rose 3.7%, reaching $310.8 million, which mirrors double-digit organic revenue growth out of the nuclear medicine end market, canceled out by weaker RTQA organic revenue; for 2026 we anticipate double-digit organic revenue growth from the nuclear medicine end market, along with a bounce back to mid-single-digit plus organic revenue growth in RTQA. RTQA ought to recover on European hardware sales and broader worldwide uptake of our software platform, plus several new product launches. At the same time, we project roughly flat dosimetry organic revenue in 2026 as a result of softer hardware sales. We're heartened by the uptake of InstaVUE, especially the feedback coming from the nuclear power end market. Adjusted EBITDA for the Medical segment rose in Q4 even with revenue softer than a year ago. Q4 was up 5.1% to $34.9 million, with margins expanding 350 basis points, largely driven by procurement savings of about 100 basis points plus 250 basis points stemming mostly from OpEx in-year initiatives. For the full year, meanwhile, adjusted EBITDA rose 11.2% to $116.3 million. Full year adjusted EBITDA margins widened 260 basis points thanks to procurement and comparable OpEx in-year initiatives. On the top line, Medical had a hard year, yet the margin growth and the team's dedication to cost and productivity give me encouragement. Let's go to Slide 21. You can observe the pronounced gain in adjusted free cash flow this year. Adjusted free cash flow for 2025 came to $131 million, roughly twice 2024's $65 million. The 2025 result amounts to a 57% conversion of adjusted EBITDA. This step change in 2025 performance came from better earnings, lower net interest expense thanks to capital structure improvements, and reduced CapEx. Keep in mind, we shrank our Term Loan B from $695 million down to $450 million and refinanced to SOFR plus 200; we also brought out 2 convertible notes in 2025 carrying 0.25% and 0% coupons; those moves brought our 2025 pro forma total cost of debt down to 2.9%, compared with 7.4% in 2024. Looking at 2026, we anticipate growing our adjusted free cash flow while holding a comparable conversion rate, in line with our long-term guidance. Prior to opening the lines for Q&A, allow me to offer some extra detail regarding 2026. Looking at full year 2026, our expectation is that Q1 will be the softest quarter for revenue as well as adjusted EBITDA. As for the remaining 2026 phasing, we expect it to line up with prior years. For Q1 2026, total organic revenue growth should come in at low single digits. For Medical, we’re looking at organic revenue growth in the mid-single digits, and Nuclear and Safety are probably going to be flat. When it comes to organic growth in Nuclear and Safety, our sensing business volume in nuclear power is going to be down because 2025 was a tough comparison, thanks to how projects were timed. That has an effect on both revenue and margins. In Q1 2026, total enterprise EBITDA margin is expected to be lower than it was in Q1 2025, even though the Medical segment should see margin expansion. Keep in mind that Paragon’s full impact is now part of Q1, and that dilutes overall margins. We expect margin expansion to come back in the back half of the year and for the full year. As Tom said, 2026 adjusted EPS now reflects stock-based compensation. We made this change so it better reflects the true cost of doing business; beyond the full year guidance Tom took you through, there are more modeling assumptions in the appendix. With that, I’ll have the operator open the line for questions.
Andy Kaplowitz
analystTom, when I consider that sizable pipeline of opportunities you have, I realize that scheduling for big projects is usually tricky. Yet looking back twelve months, the figure stood between $300 million and $400 million, whereas today it exceeds $400 million — a mid-teens increase. Clearly, your backlog excluding Paragon rose substantially during Q4 '25. So could we take that pipeline and conclude it ought to produce double-digit backlog growth in '26? And given that nuclear power now accounts for nearly 50% of your sales, do you feel confident enough to state that?
Tom Logan
executiveIndeed, Andy, I believe you've identified the core issue precisely — the scheduling of major projects, especially regarding new reactor construction and similar endeavors involving tremendous complexity, truly dictates how timing plays out. We attempt to address this by assigning probability estimates for when bids get awarded, their size, likelihood of winning, and so forth. Ultimately, though, it stays a moving target. Thus I'm reluctant to affirm that or to establish a strict link between those bigger projects — which by definition exceed $10 million in revenue — and the anticipated schedule. What I can tell you is that we're quite pleased with that situation. Considering the caliber, and as Brian mentioned, our right to win among that set of major projects, combined with the fundamental trends, especially across the nuclear power vertical, we're optimistic about how that will eventually generate a speeding-up growth rate.
Andy Kaplowitz
analystThanks, that helps, Tom. Now, this one could be for Brian or for Tom — I found the Q1 guidance interesting, because Medical is back at mid-single digits. Clearly, things get somewhat softer toward the end of the year, so is that about comparisons? Do you anticipate a fairly fast rebound in markets such as Europe and China? Perhaps you could share a bit more detail about what Medical's path should look like in '26 for that mid-single-digit growth to be achieved?
Brian Schopfer
executiveYes. I think — I mean, clearly, as the year progresses, we're somewhat stronger in '25 during the first half in Medical, particularly Q2, incidentally, since — we sent a great deal of product into China, Andy. So the second half, clearly, is somewhat simpler than the first half. Yet the team appreciates the trend they're observing in the — even here during Q1 and really throughout all 3 businesses. So that's — at present, that's what we're observing. And we'll provide an update once we finish Q1; though I believe the key point is that we thought very carefully, and typically we don't provide quarterly — excessive quarterly guidance, and we wanted to ensure we provided appropriate guidance here.
Joe Ritchie
analystLet's spend a moment on the first quarter, just to confirm we've got it right, since you also have the accretion from Paragon flowing through. Whether seasonality exists in this business, I'm not sure. Still, my guess is we're arriving at something like an EBITDA figure in the mid to high 50s. I simply want confirmation that our directional thinking is correct.
Brian Schopfer
executiveYes. Well, look, the number isn't something I'll hand over; however, I'd say this — to start with, for Paragon, the opening quarter will also be its softest. So yes, quarters three and one will be the ones that — seasonality there resembles Mirion's, in which the first and third quarters come in lighter than the second and fourth. Naturally, the nuclear power business largely tracks the outage season; that's the way I'd frame it. Given a softer first quarter at Mirion plus the dilutive margin effect on the Paragon side, I would — we just — I'd caution you to think carefully about how margin expansion gets modeled in Q1. And as I said earlier, our sensing business delivered a really robust Q1 a year ago, and that business has tremendous leverage. So with somewhat lighter volume there, you're probably — you will certainly witness some margin contraction within the legacy Mirion business, on top of Paragon's dilution. That's roughly the color I'd offer regarding Q1, without actually providing a number.
Joe Ritchie
analystAll right. That's useful, thanks Brian. So then, obviously, bookings came in really strong during this period — even stronger than we had modeled, including after that funnel you shared at the close of the prior period. Tom, perhaps you could — I realize you mentioned that $400 million pipeline, the big project opportunities lined up for 2026. Could you speak to what you're hearing from customers, and what sort of win rates we ought to assume moving ahead? Would you say your win rates are trending up? Any further detail on that pipeline and your commercial momentum?
Tom Logan
executiveSure. Joe, in the past we haven't discussed win rates, but the key point I want to make is how much Certrec and Paragon are changing the manner in which we work with customers generally. I'll talk mostly about Paragon, though the same logic applies pretty much across the board. Paragon was started and built up by its CEO, Doug VanTassell, who is a genuine star. Within the nuclear sector, he is extremely well recognized and highly regarded. Because what they sold differed fundamentally from what we have sold, their commercial approach has traditionally demanded far greater closeness to the customer than Mirion's go-to-market approach does. As Doug and I have built a solid working relationship and concentrated on the plan for bringing the two companies together, one of the earliest openings we identified — and are clearly pushing hard to capitalize on — is that commercial momentum, since pairing Paragon's closeness to customers with a substantially wider set of solutions that we think is distinctive along numerous dimensions should help us build still more momentum. That applies not just to the operating fleet — which, once again, represents roughly 80% of our entire nuclear power revenue — but also as we work with reactor designers, the NSSS companies, on new utility-scale efforts, and as we deal with essentially every SMR company across their respective programs. So we view that situation as a net positive; we are hopeful and expect that it will start to show as we build more momentum; and in the end, if we were discussing actual win rates — which we aren't — my expectation would be for those to get better.
Joe Ritchie
analystGreat. That's really useful. Maybe I can fit in one more. Brian, regarding Medical, you brought up the OpEx initiative. Margins came in very strong this quarter. When we consider the starting point for full year 2026, should we expect that, across a full year, your Medical business still delivers incremental margin in that 50% range, given the initiatives and the traction you're achieving?
Brian Schopfer
executiveYes. Look, I'm anticipating fairly solid margin expansion once again in '26; it definitely won't reach the level we had in '25, though. That's roughly my view on it. Again, I'd say the 50% incremental is fine. It might be slightly elevated, but it will remain quite strong and robust.
Tomohiko Sano
analystTurning to the 2026 guidance, which puts adjusted EBITDA margins between 25% and 26% — does the 30%-plus EBITDA margin target for 2028 still stand? And should we be modeling roughly 200 bps of margin expansion across 2027 and 2028 to get there?
Tom Logan
executiveTomo, I'm not walking away from that. Keep in mind the headwinds hitting us on this have partly been tariffs, and partly the near-term dilutive margin effect tied to the Paragon deal as a whole; but the offsetting tailwinds start with growth. Absorption is our strongest trend right now; and with the extremely high operating leverage embedded in the business, as we keep pushing a stronger top line dynamic, absorption matters a great deal. The second piece is continued self-help. We called out 100 bps of margin gain from procurement this year. That work isn't finished. Plenty more remains, across legacy Mirion and the newly acquired companies alike. Then beyond that comes our whole business system, as we focus on continuous improvement and better efficiency overall. The third piece, though, is turning much more concrete, and I'm certain it comes up on many calls — AI. AI carries enormous weight when we consider customer-facing applications and what that means for both margin profile and top line growth. As we harness it, we believe it will let us mix up to a degree. It also drives internal productivity. Last year we rolled out 17 bespoke internal AI applications aimed at boosting productivity, with another 7, I believe, in development; and that pace of change keeps improving. We're adding resources in AI; we brought on our first Chief AI and Digital Officer, Shahmeer Mirza, who has a very clear and compelling vision of what we can do and what we must do on the customer-facing side and for internal productivity. And we're quite bullish on it overall. So to be clear, reaching 30-point EBITDA margins is no gimme putt. There's a lot of wood to chop. That said, I still see a pathway, and Brian and I keep encouraging and motivating the organization to go after it.
Tomohiko Sano
analystThanks, Tom. Now a follow-up regarding AI. Given the executive appointments you just outlined, could you share what the main KPIs are for the near and medium-term objectives of your AI and digital plans?
Tom Logan
executiveSure. Those are genuinely still being worked out at this point, given that Shahmeer has been with us for just a few months now. So we aren't at a stage yet where we'll be sharing that with the broader investor community; however, what I can say is that we're seeing extremely compelling opportunities to capitalize on when we consider customer-facing applications, capitalizing on our native footprint, since we're present in virtually every operating nuclear power plant globally. That sits in the upper 90% range. And more and more, I believe there's a perspective — and a defensible one — that possessing that core sensor presence is going to be critically important when we consider things that could ultimately, in this area, affect a power plant's overall efficiency, how hot it can be run, how to handle load balancing more effectively, how to speed up start-ups following shutdowns, and so on. So there's an enormous amount of work underway, not just in the nuclear vertical, but in medical, in labs and research, and we're very advanced in defense, among others. So it's truly going to affect and shape our agenda from a customer-facing perspective across all key verticals, and internally too. We've built up considerable momentum when it comes to integrating both bespoke tools that our team has created. And on top of that, simply leveraging the capabilities that are increasingly embedded within all the different third-party software applications we use overall; so to sum all of that up, we aren't ready yet to guide the key metrics around AI, but I believe it's important to point out that our effort here is significant, our momentum is building, and we see great promise here.
Rob Mason
analystBrian, if I caught what you said about Paragon correctly, you anticipate roughly 25% growth on a pro forma basis for '26 in that segment. From what I remember, at the time you bought it, it was expanding at a rate in the low teens. So a few things I'd like to ask: what's behind that pickup? And then, Tom, to the degree that you mentioned this tip of the spear idea, what might that larger step-up in growth mean for the wider Mirion nuclear power business across the coming couple of years?
Brian Schopfer
executivePerhaps I'll handle the first portion and you handle the second. Just briefly, to start, Paragon has solid coverage. In fact, looking ahead, they have stronger comforts than Mirion does for next year. So one factor driving this, I believe, is simply the order growth we witnessed in '25. Another factor, I think, is that in '26 they're clearly broadening their markets somewhat into the DOE landscape, a vertical that didn't see as much revenue growth during the prior year. So those 2 things, taken together, are what give us confidence that we can reach those numbers. That said, it's a remarkable team, and they keep putting good wins on the board.
Tom Logan
executiveYes. So Rob, when it comes to the strategic side of things, I'd say the implications are significant. Paragon, once again, is a remarkable business with remarkable people, and there's a very strong cultural match and fit with Mirion, but the strategic alignment is also remarkable. I mean, we've laid out what are sort of the clear and main priorities when it comes to uniting the two businesses from a synergy perspective, especially when it comes to commercial momentum broadly, our capacity to support them in generating additional international expansion, and their capacity to support us in building a tighter link and relationship, and greater customer closeness across North America. But the strategic consequences over the longer haul essentially are, first, we believe we can capture additional wallet share from the installed base on a combined footing. We believe 1 plus 1 will equal 2 plus in this case. Second, when it comes to the SMR community, Paragon has been quite aggressive and quite successful in pursuing that market, as have we, yet the pairing of the two businesses in that specific space is truly, truly significant, not just when it comes to the SMR players themselves, but also when it comes to the wider industry, both the operating fleet and the developing utility scale reactors. One of the traditional innovation problems described in The Innovator's Dilemma, that classic Silicon Valley book, is the problem that businesses frequently have a tendency to concentrate on the near-term requirements of their top customers at present; and one of the fascinating aspects of SMRs is that, because of the advanced technologies they are putting to use, and because of the speed at which they are pushing toward huge, bold results, it is compelling a different degree of innovation across the industry; and I'm pleased with our position here. I'm pleased with where we stand in terms of how this is developing broadly. And though it's an extremely hard market to forecast, we do think there will be successful SMRs coming forward probably sooner than most people anticipate. And we think the innovation we are taking part in and, to some extent, are propelling will subsequently spread more widely into both the operating fleet and a number of the utility scale reactors. So I mean, the consequences here, in our view, are considerable. We're delighted that we managed to complete this transaction and feel fairly good about the art of the possible here broadly.
Rob Mason
analystThanks, Tom, that's useful. And just very fast as a follow-up, perhaps to broaden this out to the current fleet on the nuclear side — it's quite a busy year for the NRC when it comes to license renewals here in the U.S., and maybe that isn't shocking, but you might be seeing less resistance to those going through. In terms of orders, how does that amount of activity, that amount of renewal activity, show up for you? I mean, did that already appear in backlog? Or does it sit in the pipeline you're looking forward to? Or how exactly does it show up?
Tom Logan
executiveYeah. To a certain extent, I'd say yes. Obviously, we recorded 11% growth in nuclear power during the prior year; and surely, certain portions of that were shaped by those themes. But the main forces at play here — the one you mentioned, namely license renewals — plus you also have to consider uprates, meaning raising the authorized output of a nuclear plant. And beyond that, a basic requirement for modernization, especially when it comes to instrumentation and control systems in general. Every one of those themes matters greatly for the worldwide fleet, not only the North American fleet as a whole. And it keeps growing. The clearest illustrations would be the formerly shut-down plants that are returning to service, and that would take in Palisades, Three Mile Island and Duane Arnold. Our content is substantial in every one of those. And it isn't completely traded. That keeps developing. So I believe this trend will keep growing. I think it's self-evident, once more, simply because of the severe shortage of global electrical generating capacity; it's difficult to imagine an edge case where that trend disappears entirely. And I think that's basically good for us and the solution sets we bring to the marketplace.
Jeff Grampp
analystRegarding the '26 guidance, I'm wondering whether any portion comes from that $150 million in large orders you secured during '25, or whether the bulk is anticipated in '27 and later.
Brian Schopfer
executiveYeah, good question. Some of those big orders from '25 were certainly booked late in Q4. But as we've discussed before historically, the opening year on these bigger contracts is usually the smallest, and then things build up more — roughly after 18 months, moving into year 2, 3, 4. So there is a bit, though I wouldn't call it the largest component of those businesses on an annual basis.
Jeff Grampp
analystGot it, that helps. For my follow-up, I'd like to point to Slide 23, if I'm not mistaken. You mentioned SMR as a larger contributor to growth in 2026. Could you put that in a bit more context? And stepping back for a moment, how significant do you expect SMRs to become for Mirion's growth narrative in the years ahead?
Tom Logan
executiveYeah. Jeff, putting that in context is tough, given how many SMR projects exist worldwide — by one screening approach, well over 100 separate projects in total; we've said that contractual relationships have been awarded with over 20 of these players thus far. And as we mentioned, we're hoping to keep pushing further; covering everyone is the goal; a relationship with each major SMR sponsor is what we want. On hard metrics, the orders we've booked on the SMR side are probably the primary measure. In the presentation, we pointed to the remarkable growth in order intake during 2025. That said, once more, quantifying particular KPIs for this market beyond orders and beyond engagement is extremely, extremely difficult.
Brian Schopfer
executiveYeah, if you look at it across the whole company, that's under 3% of overall revenue when we project into '26, and last year it came in below 2%, possibly even beneath 1.5% in '25. So absolutely, expansion is happening, no question, though within the bigger picture it isn't significant, yet it's definitely a area we stay enthusiastic about, and it's a thing that keeps obviously driving bookings. So perhaps that gives a bit more context when we're considering '26.
Chris Moore
analystYeah. So clearly, when it comes to M&A, Paragon is what everyone's been talking about. Perhaps you could say a bit about the Certrec deal. You've had it for just over half a year. What have you observed so far, and is there anything investors might be missing? It's clearly a lot smaller than Paragon, but it also expands your nuclear power portfolio and reach, as we were just discussing SMRs and so on. Could you give us a bit more detail there?
Tom Logan
executiveSure. Chris, essentially, Certrec's core business is regulatory compliance provided as an outsourced service. Roughly 50% of what they do runs on a SaaS platform they built, and that platform is truly the North American industry standard, holding a very strong dominant position, not just in nuclear power but also, more broadly, across the bulk electrical grid. It's backed by an extraordinary treasure trove of data. They hold more than 15 terabytes of licensing and regulatory information serving their customers. That means literally every permit, all design drawings, and each regulatory action affecting the sectors they serve. This allows engineers and operators at customer locations to rapidly determine what regulatory problems they might face. When a component fails, they can see how other organizations dealt with the same situation. When there's a routine regulatory filing, it can be automated. And we really like that element. Again, it's a fantastic platform and fantastic people. The emphasis we have here has several dimensions, but 2 stand out to me. First, given the data-rich setting they possess, we've been intensely focused on using AI to leverage that data set. In our industry, 15 terabytes represents an ocean of data, and there's plenty we can do to boost the speed of that data and enhance the information quality, the feedback, and the tools we deliver to our customers. Second, there's the opportunity to extend it more widely, considering once more Mirion's overall global strength. So it's a jewel of a business. We're delighted to have it within the Mirion DNA. And I believe it will be a significant AI story for us going forward.
Yuan Zhi
analystPerhaps we could shift our focus to nuclear medicine. As part of its U.S. investment, Novartis is constructing its fourth radiopharmaceutical manufacturing facility in the United States, specifically in Florida. I'm curious about the economics for Mirion when a manufacturing site of such large scale gets built. Tom or Brian, could you also share your high-level plans for nuclear medicine in 2026?
Tom Logan
executiveYes. Nuclear medicine, once again, is an exciting vertical. You saw, Yuan, that we issued a press release today about moving one of our best and brightest executives, Shelia Webb, who until now served as our Chief Digital Officer, and we've shifted her to lead our entire nuclear medicine business. That includes both the software piece, ec2, and the legacy hardware operations, which covers dose calibration instruments, clinical instruments such as thyroid uptake systems, the full ecosystem in that space. We perceive a strong and compelling chance to keep pushing a greater level of integration, to keep swiftly advancing the capabilities of our software platform as a whole, and to do so in a manner that generates more traction, more pull for the hardware side. But Shelia is also engaging more widely with the team, having been very proactive in forming strategic relationships with major participants in nuclear medical infrastructure; so when we consider all the key players, the drug makers, the isotope producers, the CDMOs, the radiopharmacies, the clinicians and IDNs. She has been leaning into that. And our focus has really been on developing strategic traction with major players here to try and drive, again, just greater velocity of the opportunity set on both the hardware and software side combined. And I like the direction that's heading. Again, we keep seeing this as a very exciting market. We believe this modality in cancer care is relevant and a true game changer, and we like where we sit.
Brian Schopfer
executiveOne more point regarding Novartis — on the nuclear medicine front, what we're really zeroed in on is getting those Nuclear and Safety product lines pulled through. Shelia gives us an edge there, since she's familiar with both of those businesses. And when it comes to your specific question about Novartis, that's honestly where I believe we'll be in a position to actually shift things.
Tom Logan
executiveRight. And when you consider that, building on Brian’s point, there are 3 major production facilities they operate in the U.S. Yuan, and 2 additional ones are under construction. A great deal of equipment tied to what we provide is needed at these sites — things such as laboratory QC equipment, including gamma spec instrumentation, radiation monitoring for area monitors, and affluent classical health physics instrumentation like survey instruments and dosimeters, dose of record for legal dosimetry, dose calibration instruments, et cetera. So it’s — clearly they are a significant player. Our hope is to support them in the most comprehensive way possible.
Tom Logan
executiveGood day, everyone, and thanks for joining us. Once more, we feel a lot of enthusiasm about wrapping up what has truly been a significant 12 months for Mirion as a whole, regarding how our strategy keeps developing as a company and regarding the crucial operational and financial achievements we've laid out. Yet at a deeper level, our outlook stays quite positive concerning the trends in our vertical markets and concerning what we can do as a whole; so we're eager to walk through this path alongside all of you across the quarters ahead and extend our best wishes to each of you. Many thanks.
Operator
operatorThanks for joining us. That brings today's call to a close. At this point, you're welcome to hang up. We appreciate you taking part.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Mirion Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Mirion Technologies, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Mirion Technologies, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.